Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined diuretic therapy versus standard diuretic therapy in chronic congestive heart failure
2022-003314-37Phase 3Active
- Sponsor
- Centro Cardiologico Monzino
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetazolamide and metolazone in heart failure (HF) (2 arms), sponsored by Centro Cardiologico Monzino. Primary endpoint: Short- to medium-term rehospitalizations. Started Jan 2023; status: active.
02
Drugs
acetazolamidemetolazone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2022-003314-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003314-37.